Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival

• Published in: Acta oncologica 2016-01, Vol.55 (4), p.486-495
• Main Authors: Maleux, Geert, Deroose, Christophe, Laenen, Annouschka, Verslype, Chris, Heye, Sam, Haustermans, Karin, De Hertogh, Gert, Sagaert, Xavier, Topal, Baki, Aerts, Raymond, Prenen, Hans, Vanbeckevoort, Dirk, Vandecaveye, Vincent, Van Cutsem, Eric
• Format: Article
• Language: English
• Subjects: Aged; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Colorectal Neoplasms - therapy; Disease-Free Survival; Embolization, Therapeutic - adverse effects; Embolization, Therapeutic - methods; Female; Humans; Hypertension, Portal - etiology; Infusions, Intra-Arterial - adverse effects; Infusions, Intra-Arterial - methods; Liver Neoplasms - mortality; Liver Neoplasms - secondary; Liver Neoplasms - therapy; Male; Middle Aged; Retrospective Studies; Salvage Therapy - methods; Treatment Outcome; Yttrium Radioisotopes - therapeutic use
• ISSN: 0284-186X; 1651-226X
• DOI: 10.3109/0284186X.2015.1101151

The purpose of this study was to retrospectively assess the technical and clinical outcomes, overall survival and prognostic factors for prolonged survival after yttrium-90 ((90)Y) radioembolization as a salvage therapy for patients with chemorefractory liver-only or liver-dominant colorectal metastases. From January 2005 to January 2014, all the patients selected for (90)Y radioembolization to treat chemorefractory colorectal liver metastases were identified. Demographic, laboratory, imaging and dosimetry data were collected. Post-treatment technical and clinical outcomes were analyzed as well as overall survival; finally several factors potentially influencing survival were analyzed. In total 88 patients were selected for angiographic workup; 71 patients (81%) finally underwent catheter-directed (90)Y microsphere infusion into the hepatic artery 25 days (standard deviation 13 days) after angiographic workup. Median infused activity was 1809 MBq; 30-day toxicity included: fatigue (n = 39; 55%), abdominal discomfort (n = 33; 47%), nausea (n = 5; 7%), fever (n = 14; 20%), diarrhea (n = 6; 9%), liver function abnormalities and elevated bilirubin (transient) (n = 3; 4%). Gastric ulcer was found in five patients (7%). A late complication was radioembolization-induced portal hypertension (REIPH) in three patients (4%). Median time to progression in the liver was 4.4 months. Estimated survival at six and 12 months was 65% and 30%, respectively, with a 50% estimated survival after 8.0 months in this group of chemorefractory patients. Prognostic factors for worse survival were high preprocedural bilirubin, alkaline phosphatase and tumor volume levels. (90)Y microsphere radioembolization for chemorefractory colorectal liver metastases has an acceptable safety profile with a 50% estimated survival after 8.0 months. Pretreatment high bilirubin, alkaline phosphatase and tumor volume levels were associated with early death.